まとめ
研究者らは,ピンタ病変からの液体でウサギに接種した. 一匹のウサギは,トレポネメタを含む病変を発症し,ヒトのボランティアに感染し,Treponema carateumがピント剤であることを確認した.
科学分野:
- 医学微生物学 医学微生物学
- 皮膚科 皮膚科について
- 感染症 感染症は感染症です.
背景:
- ピンタは,皮膚に影響する三角膜感染症です.
- ピンタ病の原因は,Treponema carateumとして知られている.
- 感染と実験モデルは,ピンタ病原性を理解する上で極めて重要です.
研究 の 目的:
- ウサギのピンタ病変の感染性を調査するために.
- 実験的な病変におけるTreponema carateumの役割を確認する.
- ピンタ感染を研究するためのモデルを確立する.
主な方法:
- ウサギの部皮の皮内注射で,ヒトのピンタ病変からの血清液を注入する.
- ダークフィールド顕微鏡とフォンタナ-トリボンデオ染色法で,トレポネマタを特定する.
- ウサギの病変からの排泄物で,人間のボランティアに接種.
主要な成果:
- 接種後105日後に1頭のウサギにパプルが形成され,侵食した病変へと進行した.
- トレポネメータはウサギの病変の排泄物で特定されました.
- ウサギの病変エクスズダートは,ヒトのボランティアの典型的なピンタ病変を成功裏に誘導しました.
結論:
- ピンタ病変液でウサギの実験的予防接種は,Treponema carateumを含む病変を引き起こす可能性があります.
- この研究は,Treponema carateumが pinta.の病原体であることを確認しています.
- ウサギのモデルは,ピンタ感染のさらなる調査のための手段を提供します.
さらに関連する動画
10:39Preparation of Pancreatic Acinar Cells for the Purpose of Calcium Imaging, Cell Injury Measurements, and Adenoviral Infection
Published on: July 5, 2013
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
関連する概念動画
Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Pancreatic Juice and Secretion
Pancreatic juice is a clear fluid produced by the pancreas, containing water, salts, sodium bicarbonate, and enzymes vital for digestion in the small intestine. It helps break down large molecules, facilitating nutrient absorption.
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
